𝔖 Bobbio Scriptorium
✦   LIBER   ✦

PRS30 Identifying the Patient Population Where Treatment of Severe Allergic Asthma with Omalizumab (XOLAIR®) Exhibits Optimal Cost-Effectiveness in Australia

✍ Scribed by Tilden, D.; Cottrell, S.; Tocchini, L.; Frenzel, C.; Bonney, M.A.


Book ID
122282254
Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
72 KB
Volume
14
Category
Article
ISSN
1098-3015

No coin nor oath required. For personal study only.